This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Dr. Caleb Bates focuses his practice on intellectualproperty law, with an emphasis on patentprosecution, strategic counseling, and worldwide patent portfolio management in the pharmaceutical and biotechnology fields. with highest honors from the Georgia Institute of Technology in 2009. He received his J.D.,
Between 2009 and 2013, the rate at which applications subject to the former (i.e. In particular, expedited examination under the Global PatentProsecution Highway (GPPH) program rose from just 2.7% Finally, the most recent data confirms (once again) that the duration of patentprosecution (i.e. in 2019/20.
of the Patent Act has brought about a significant shift in the Canadian approach to file wrapper estoppel by enabling the introduction of a patent’sprosecution history during claim construction. and whether it should cover communications between patentees and foreign patent offices. TA Foods Ltd. 2021 FCA 7 Section 53.1
The Drug and the patent. The international filing date of the patent application for EO is May 21, 2003 and the proprietary right over EO was granted to GlaxoSmithKline LLC in 2009. Therefore, the patent will remain active till May 21, 2023, by the virtue of Section 53 (1) of the Patent Act. Relying on Novartis v.
Recently, India and a group of 4 European countries- Iceland, Liechtenstein, Norway, and Switzerland (EFTA) signed a Trade Economic Partnership Agreement (TEPA) on a variety of trade related issues, including intellectualproperty rights. Sreenath is an independent legal researcher and Adjunct Faculty of Law at Ramaiah Law College.
Endeavors with similar objectives have been made earlier as well, e.g., through the Public Funded Research and Development (Protection, Utilisation and Regulation of IntellectualProperty) Bill, 2007 aka Indian Bayh Dole Act. Patent Opposition: Navigating SpicyIP’s September pages, I chanced upon a 2009 piece from Prof.
We organize all of the trending information in your field so you don't have to. Join 9,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content